Kelsey Klute, MD
Medical Oncology · Omaha, NENPI 1396056149
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 26.6% of the total. Reporting peaked in 2024 at $8,033 and has fallen 60.3% since, to $3,191 in 2025.
Across 28 payments — averaging $656.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$5K
- Array Biopharma Inc$4K
- Partner Therapeutics, Inc.$4K
- E.r. Squibb & Sons, L.L.C.$2K
- Daiichi Sankyo Inc.$2K
- Astrazeneca UK Limited$1K
- plus $15 from 1 others
Across 20 payments — averaging $3534.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$49K
- Pharmacyclics LLC, An Abbvie Company$15K
- Pfizer$7K
What the payments were for
- Consulting fees$6,86337%
- Speaking & faculty fees$8,88548%
- Travel & lodging$1,79610%
- Food & beverage$8495%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 4 | $4,887 |
| Array Biopharma Inc | 2 | $4,400 |
| Partner Therapeutics, Inc. | 9 | $4,188 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,150 |
| Daiichi Sankyo Inc. | 1 | $1,713 |
| Astrazeneca UK Limited | 10 | $1,040 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TukysaTucatinib | 11 | $249,339 |
| CreonLipase/Protease/Amylase | 18 | $51,024 |
| EliquisApixaban | 45 | $36,248 |
| Gabapentin | 15 | $870 |
| Prochlorperazine Maleate | 57 | $674 |
| Oxycodone Hcl | 34 | $503 |
| Ondansetron Hcl | 51 | $454 |
| Olanzapine | 11 | $408 |
| Dexamethasone | 13 | $350 |
| Potassium Chloride | 12 | $302 |
| LoperamideLoperamide Hcl | 11 | $280 |
| Pantoprazole Sodium | 11 | $207 |
| Omeprazole | 15 | $195 |
| Duloxetine Hcl | 14 | $160 |
| Famotidine | 17 | $65 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Omaha
- Matthew LunningOmaha$631K
- Jairam KrishnamurthyOmaha$63K
- Benjamin TeplyOmaha$22K
- Michael HaddadinOmaha$7K
- Laxmi Narayana BuddharajuOmaha$7K
- Nicole ShonkaOmaha$3K
- Alissa MarrOmaha$319
- Lyudmyla BerimOmaha$263
- Haris ZahoorLincoln$6K
- Irfan VaziriLincoln$605
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.